https://fer-1inhibitor.com/mul....timerization-and-als
Median OS of pRCC vs. ccRCC was 8 vs. 4 months for no treatment (NT), 11 vs. 12 months for targeted therapy alone (TT), 17 vs. 35 months for cytoreductive nephrectomy alone (CN) and 18 vs. 25 months for mix of CN with TT. CONCLUSIONS Metastatic pRCC patients exhibit bad success, aside from treatment gotten. Moreover, pRCC customers are more inclined to present nodal metastases, contrasted to ccRCC customers, as shown by twofold higher rates of lymph node inva
Curtir
Comentario
Compartilhar
